Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.

Source:http://linkedlifedata.com/resource/pubmed/id/17146157

Download in:

View as

General Info

Authors

Furukawa K, Hatake K, Akiyama F, Kasumi F, Furukawa K, Tajiri T, Ito Y, Mizunuma N, Takahashi S, Horikoshi N, Sakamoto G, Sawaki M

Affiliation

Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. keikofuru@triton.ocn.ne.jp

Abstract

In breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.

PMID
17146157